🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “insulin” Clear

  1. A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  2. A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

    NovoThirteen

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  3. Insulin Lispro

    HALOZYME THERAPEUTICS, INC.

    Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  4. Insulin Peglispro

    Eli Lilly and Company

    Healthy Volunteers

    phase 1 small molecule completed

    1 trial

  5. Insulin aspart

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    phase 1 small molecule completed

    1 trial

  6. Insulin degludec injection, RD15003

    Sunshine Guojian Pharmaceutical (Shanghai) Co.,

    Type 2 Diabetes

    phase 1 mab completed

    1 trial

  7. Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.

    NovoThirteen

    Type 2 diabetes

    phase 1 other active

    1 trial

  8. Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

    NovoThirteen

    Type 2 Diabetes

    phase 1 other active

    1 trial

  9. Oshadi Oral Insulin

    BRIGHT MINDS BIOSCIENCES INC.

    Diabetes

    phase 1 small molecule completed

    1 trial

  10. INSULIN GLARGINE

    Sanofi-aventis Healthcare Pty Ltd

    Diabetes mellitus II

    approved small molecule active

    1 trial

  11. INSULIN GLARGINE (HOE901)

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule terminated

    1 trial

  12. Insulin

    The First People's Hospital of Lianyungang

    Brain Injuries

    approved small molecule active

    1 trial

  13. Insulin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pancreatitis, Acute

    approved small molecule active

    1 trial

  14. Insulin

    The First People's Hospital of Lianyungang

    Acute Pancreatitis

    approved small molecule active

    1 trial

  15. Insulin Glargine

    Eli Lilly and Company

    Diabetes Mellitus, Type 2

    approved small molecule completed

    1 trial

  16. Insulin Glargine

    Sanofi Pasteur

    Diabetes Mellitus, Type 2

    approved small molecule completed

    2 trials

  17. Insulin glulisine

    Sanofi Pasteur

    Diabetes Mellitus, Type 1

    approved small molecule completed

    1 trial

  18. Insulin lispro low mixture

    Eli Lilly and Company

    Type 2 Diabetes Mellitus

    approved small molecule completed

    1 trial

  19. Pioglitazone and insulin

    Takeda

    Diabetes Mellitus

    approved small molecule completed

    2 trials

  20. Rapid Acting insulin with pre-treatment of rHuPH20

    HALOZYME THERAPEUTICS, INC.

    Type 1 Diabetes Mellitus

    approved small molecule completed

    1 trial

  21. SEMAGLUTIDE, SEMAGLUTIDE, INSULIN GLARGINE, DAPAGLIFLOZIN

    Fondazione Telethon ETS

    type 2 diabetes

    approved small molecule active

    1 trial

  22. Subcutaneous glargine insulin

    Lxo Ireland Designated Activity Company

    Diabetes Mellitus

    approved small molecule completed

    1 trial

  23. biphasic insulin aspart 30

    Novo Nordisk A/S

    Diabetes

    approved small molecule completed

    2 trials

  24. insulin detemir

    Novo Nordisk A/S

    Diabetes

    approved small molecule completed

    2 trials

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources